Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) EBITDA (2020 - 2023)

Historic EBITDA for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$30.7 million.

  • Therapeutics' EBITDA fell 3608.6% to -$30.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$116.7 million, marking a year-over-year decrease of 3945.95%. This contributed to the annual value of -$116.7 million for FY2023, which is 3945.95% down from last year.
  • According to the latest figures from Q4 2023, Therapeutics' EBITDA is -$30.7 million, which was down 3608.6% from -$31.3 million recorded in Q3 2023.
  • In the past 5 years, Therapeutics' EBITDA ranged from a high of -$12.2 million in Q2 2020 and a low of -$31.3 million during Q3 2023
  • Over the past 4 years, Therapeutics' median EBITDA value was -$18.6 million (recorded in 2021), while the average stood at -$20.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 1339.54% in 2022, then crashed by 4951.06% in 2023.
  • Over the past 4 years, Therapeutics' EBITDA (Quarter) stood at -$13.0 million in 2020, then plummeted by 40.0% to -$18.2 million in 2021, then fell by 23.89% to -$22.5 million in 2022, then crashed by 36.09% to -$30.7 million in 2023.
  • Its EBITDA stands at -$30.7 million for Q4 2023, versus -$31.3 million for Q3 2023 and -$25.8 million for Q2 2023.